This forum is for questions about medical issues and research aspects of
Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new
Hepatitis Social/Living with Hepatitis forum
http://www.liverfoundation.org/education/webcasts/
Inhibitors of HCV Posttranslational Processing
Peptidomimetic Inhibitors of NS3/4A Serine Protease
NS3 and NS4A are nonstructural HCV proteins that form a complex that is proteolytically cleaved by a serine protease. This cleavage is required for viral replication and virion assembly. Highly selective, potent peptidomimetic inhibitors of HCV NS3/4A protease have been derived from the viral substrate of the enzyme using structure-based drug design techniques and 2 such agents have now advanced to phase II clinical trials (Table 4).
The first agent, telaprevir (previously known as VX-950), demonstrated activity in a randomized phase Ib study.[31]
The second novel NS3 protease inhibitor in phase II trials is boceprevir (previously known as SCH 503034).
Mike
General life cycle of a virus.
“A virus is basically genetic material wrapped up in a protein coat. It does not have metabolic machinery to reproduce. For reproduction the virus has to enter a cell and use the cell’s metabolic machinery.
The virus attaches to a cell via a receptor and enters the cell. Then, uncoating occurs where the protein coat is lost and the viral genome is exposed. The viral genome is both replicated and expressed (i.e. viral proteins are made). The newly generated viral proteins associate with viral genomes to build new virus particles. The new particles eventually leave the cell.”
As I understand it, Protease inhibitors interfere with the association of the new viral genomes and the new viral proteins.